Physiological and behavioral study on depressed rats model treated with Hordeum vulgare extract referenced to SSRI class

Kadry A. Elbakry¹, Naema Ibolgasm Alazabi², Nahed M. Omer³, Mohamed H. Bahnasawy⁴, Omar Abdel-Hamed Ahmed-Farid⁵,⁶*©

ABSTRACT

Objective: The aim of the present study is to investigate the effects of Hordeum vulgare aqueous extract (HVE) in a sub-chronic depression rat model. Methods: Thirty male rats were randomly divided into five groups: the first group served as a control group; the second group received i.p. injection of reserpine (Res) (0.5 mg/ kg) for 20 days, the third group received i.p. injection of reserpine plus fluoxetine (Res + Flux) (10 mg/kg p.o.) for 20 days, the fourth group received i.p. injection of Res plus HVE (1,000 mg/kg p.o.), and the fifth group received Res + Flux + HVE. Behavioral tests were measured on the 21st day of the experiment, then rats were decapitated to determine liver function [alanine transaminase, aspartate transaminase, TP, Alb, Glob, A/G], brain monoamines and their metabolites (NE, DA, 5-HT, HVA, DOPAC, 5HIAA), oxidative and nitrositive stress markers (MDA, glutathione, oxidized glutathione, NO, SOD, 8OHdG) and purinergic cell capacity (ATP, ADP, AMP).

Results: Obtained data showed neuro-degenerative effect of Res and deteriorative manifestation in liver function. Moreover, flux treatment showed an attenuated deterioration, manifested by Res for monoamines and its metabolites, and subsequently stabilized behaviors and decreased depression status with behavioral tests indicators. On the other hand, it showed initial indicators of liver alteration, presented by serum liver function and histological examination. In addition, treatment with HVE showed amelioration for behavioral, neurochemical functions, and decreased oxidative stress. The results were confirmed by the histological examination. Conclusion: HVE ameliorate depression induced by Res, stimulates monoamines and antioxidant status, decrease oxidonitrositive markers and increases cell energy capacity without side effects on liver, contrasting to selective serotonin re-uptake inhibitors, which produces initial indicators of liver damages.

Key words: Depression, Fluoxetine, Hordeum vulgare, Rats, Reserpine

INTRODUCTION

Depression is one of the most prevalent diseases in the world. Depression is a state of complete physical malaise, which affects morbidity, general health, sleep quality and eating, and subsequently disrupts physiological and neurochemical homeostasis. Causes of depression may have various sources. Depression accompanied by anxiety, which shows no clear differences between the symptoms of depression and anxiety. Bipolar depression, is accompanied by mania, a state of “high spirits”, which results in increased activity and decreasing need for sleep. The causes of depression are not known exactly, however, as with many other psychiatric illnesses, it is believed that there are several biochemical, genetic, and environmental factors that may cause depression. There is an evidence that people who suffer from depression have physical changes in the brain. In addition, hormonal imbalance can also cause this disorder. Some studies have shown that depression is more common in people with family members with history of the disease, encouraging researchers to seek out the genes that cause the disease. Environmental factors also play a critical role in depression. Depression may occur as a result of drug addiction, certain medications, or as a result of stressful life events. On the other hand, diseases, such as cancer, thyroid disease, and chronic pain, are associated with an increased risk of depression. Both environmental and genetic factors are likely to interact to facilitate the development of the disease in a complete and rapid manner. Fluoxetine, an antidepressant drug, acts as a selective serotonin reuptake inhibitor (SSRI), which has better overall safety and tolerability than older antidepressants. However, SSRIs has shown with the frequency of side effects in clinical trial data. The most troubling adverse events seen during long-term SSRI therapy may include weight gain, sexual dysfunction, as well as sleep disturbance. In depth, SSRI improves an opportunity for more available neurotransmitters to interact with any of these receptors.
or sub-type receptors. In addition, SSRI-induced skin reactions and gastrointestinal disturbances are the most frequently reported side effects. Barley (Hordeum vulgare) is considered as one of the natural substances that can improve public health. Barley is one of the famous plants that is used in the treatment of many diseases, as it contains many nutrients (such as proteins, amino acids, dietary fiber, antioxidants, vitamins, and carbohydrates). Strengthening the immunity may be due to a high level of vitamin C, which is higher in barley than orange. Barley is capable of preventing osteoporosis, since it is rich in minerals such as phosphorus, one of the most important elements for bones and teeth formation. Chen found that barley contained vitamin E, a powerful antioxidant with the ability to cross the cerebral blood barrier. Vitamin E is found in a high concentration in brain tissue and contributes to the synthesis of a number of neurotransmitters, such as dopamine. In addition, the presence of high amounts of vitamin E in blood stream stimulates mental functioning at all ages and protects the brain from degenerative diseases, including Alzheimer’s disease and strokes. Vitamin E is especially important for the maintenance of older brains, which helps to reduce appearance of cerebrovascular diseases and strokes.

The present study is aimed at examining possible protective effects of the H. vulgare extract against depression, induced by reserpine, and side effects of chemical drug (fluoxetine) in a sub-chronic model of depression.

METHODS

Chemicals

2,2-Diphenyl-1-picrylhydrazyl (DPPH) Merk EC Number 217-591-8. Methanol (HPLC grade) purchased from Loba Co, India. Perchloric acid purchased from Loba Co, India. Sulphosalicylic acid and P-aminobenzyl glutamate and pyrogallol purchased from TMMEDIA Co, India. The 1,1,3,3-tetraethoxypropane, glutathione (GSH) and oxidized glutathione (GSSG) from Sigma Aldrich (USA). Potassium dichromate, monobasic potassium phosphate, nitrites and nitrate were from Al Nasr chemicals, Abozabal (Qalybia, Egypt). All used chemicals were either HPLC or analytical grade. Neurotransmitters and cell energy purchased from Merck (NE CAS Number: 51-41-2; DA CAS Number: 62-31-7; 5HT CAS Number: 50-67-9; ATP CAS Number: 34369-07-8; ADP CAS Number: 20398-34-9; AMP CAS Number: 4578-31-8). 8-Hydroxy-2′-deoxyguanosine sigma CAS Number 88847-89-6. All spectrophotometer Kits were purchased from Biodiagnostic 29 El-Tahrer St.—Dokki—Giza—Egypt.

Animals

Adult male albino rats weighting about 150 ± 15 g were used in the present study. Animals were kept under normal laboratory conditions in the animal house of National Organization of Drug Control and Research for 1 week before the start of the experiment. Rats were to fed according to the uniformity diet.

Preparation of plant extract

The air-dried powdered of H. vulgare seeds (950 g) were extracted with 30% ethanol in soxhlet apparatus for 24 hours. The extract was evaporated to dryness under reduced pressure to give approximately 7.6% w/w solid yield residues. The yield was stored at 4°C until used.

Assay of H. vulgare amino acids

Determination of H. vulgare amino acids seeds extract was measured and explained at Figure 1 via HPLC UV detector at 254 nm and ammonium acetate gradient buffer, combined with acetonitril (pH 5.7), according to the method of Saunders et al.

Determination of free radical scavenging assay (DPPH)

The radical scavenging activity of HV aqueous extract was determined according to the method of previous study, described by Siddhuraju et al., with different doses of extract (50, 100, and 200 µg/ml) at 517 nm. The interpretation of lower absorbance indicates high free-radical scavenging activity. The respected result showed antioxidant properties of each extract, compared to rutin of the same concentration as follows: 68%, 79%, 86% for rutin and 34%, 48%, 52% for H. vulgare aqueous extract (HVE), respectively.

Experimental design

After 1 week of acclimatization period, male rats were divided randomly into five equal groups, each of six rats. Group 1 kept as control, feeding on basal diet, group 2 received reserpine i.p (0.5 mg/ kg) for 20 days day other day, group 3 received reserpine plus Fluoxetine (10 mg/kg p.o) for 20 days, group 4 received reserpine plus H. vulgare seed 70% ethanolic extract (1.000 mg/kg p.o) for 20 days. Rats were grouped and housed in a conventional clean facility, according to the guidelines of the Institutional.
Animal Ethics Committee of NODCAR. All the experimental procedures were carried out in accordance with international guidelines for the care and use of laboratory animals.

**Collection of blood samples**

At the end of the experiment, blood samples were withdrawn from the retro-orbital vein of each rat, under light anesthesia by diethyl ether, according to the method described by Moore (2000)\(^\text{25}\). Blood was allowed to coagulate and then centrifuged at 3,000 rpm for 15 minutes. The obtained serum was used to estimate the activities of liver function enzymes, total protein, total lipids, and lipid peroxidation.

**Preparation of brain samples**

Immediately after blood sampling, animals were sacrificed by cervical dislocation and the brain tissues were rapidly removed, washed in ice-cooled saline, plotted dry, and weighed. A weighed part of each brain was homogenized, using a homogenizer (Medical instruments, MPW-120, Poland), with ice-cooled saline (0.9%NaCl) to prepare 20% w/v homogenate. The homogenate was then centrifuged at 4,000 rpm for 5 minutes. The aliquot was used for the assessment of monoamines, oxidative stress markers and purine-ergic cell energy.

**Methods**

**Behavioral study**

**Open field**

The open field apparatus was constructed of white plywood of 72 \(\times\) 72 cm with 36-cm walls. Blue lines were drawn on the floor with a marker and were visible through the clear Plexiglas floor. The lines divided the floor into sixteen 18 \(\times\) 18 cm squares. A central square (18 cm \(\times\) 18 cm) was drawn in the middle of the open field\(^\text{26}\). 70% ethyl alcohol was used to clean the open field maze for each rat to avoid odor cues. The following conditions were measured. Grooming: the duration of time, which animal spent licking or scratching while stationary. Rearing: frequency of standing on their hind legs in the maze. Center Square Duration: the duration time of rats spent in the central square. Peripheral Square Duration: the duration time of rats spent in the peripheral square. Urination: number of puddles or streaks of urine. Defecation: number of fecal pellets produced.

**Forced swim**

The rats were examined in a cylindrical container (50 \(\times\) 20 cm) filled with 30 cm of 22ºC water. Generally, in this test, the water level does not let the rat rest on its tail or run away from the cylinder by climbing out. Each rat was placed in the water for 6 minutes. The time spent floating (represented immobility) was scored during the last 4 minutes. The time spent immobile was considered as an index of depression-like behavior in rodents\(^\text{27}\).

**Physiological study**

**Determination of transaminases (AST and ALT)**

Aspartate transaminase (AST) and alanine transaminase (ALT) were determined, following a colorimetric method according to Reitman and Frankel\(^\text{28}\), using reagent kit by QCA-Spain. The Principle: Aspartic
acids + α-ketoglutaric acid → AST Oxaloacetic acid + L-Glutamic acid. Alanine + α-ketoglutaric acid → ALT Pyruvic acid + L-Glutamic acid. The keto acids produced will form colored hydrazones by reaction with 2, 4-dinitrophenyl hydrazine.

**Determination of total protein**

Serum total protein evaluation was performed by the Biuret method, according to Gornall et al.\(^{29}\), using ready-made kits by Stanbio, Texas. The principle is that protein molecules contain a large number of peptides and bonds. When treated with copper ions in alkaline solution, a colored complex is formed between the copper, the carbonyl and amine groups of these peptides. As a similar reaction occurs with biuret, the term “biuret reaction” was adopted.

**Determination of albumin**

The plasma albumin was determined, using Stanbio albumin kit, purchased from Stanbio Laboratory Inc., Boerne, Texas, USA according to the method of Doumas et al.\(^ {30}\).

**Determination of globulin**

The plasma globulin was calculated by subtracting albumin values from total protein of each corresponding sample. The albumin to globulin ratio (A/G) was calculated by dividing A/G values.

**Determination of the brain monoamines and metabolite concentrations by HPLC method**

The HPLC system consisted of quaternary pump, a column oven, Rheodine injector, 20-μl loop and UV variable wavelength detector. The report and chromatogram were taken from a data acquisition program, purchased from Chemstation. The sample was immediately extracted from the trace elements and lipids by the use of solid phase extraction Chromabond column NH2 phase, cat. No.730031. The sample was then injected directly into an AQUA column 150 mm 5μ C18, purchased from Phenomenex, USA under the following conditions: mobile phase 20mM potassium phosphate, pH 2.5, flow rate 1.5ml/minute, UV 270 nm\(^ {31}\).

**Antioxidant parameters**

**Determination of brain MDA by HPLC**

MDA standard was prepared by dissolving 25 μl 1,1,3,3 tetraethoxypropane (TEP) in 100 ml of water to get a 1 mM stock solution. The working standard was prepared by hydrolysis of 1 ml TEP stock solution in 50 ml 1% sulfuric acid and incubated for 2h at room temperature. The resulting MDA standard of 20 nmol/ml was further diluted with 1% sulfuric acid to yield the final concentration of 1.25 nmol/ml, which was used as the standard for the estimation of total MDA\(^ {32}\).

**Determination of brain GSH and GSSG by HPLC**

The thiols compounds of oxidized and reduced glutathione were detected by HPLC using the previously described method\(^ {33}\).

**Determination of brain nitrites and nitrates by HPLC**

Nitrites and nitrates were determined by HPLC according to the method by Papadoyannis et al.\(^ {34}\).

**Determination of SOD in liver**

The activity of SOD was determined according to the method of Marklund and Marklund\(^ {35}\).

**Determination of brain 8-OHDG**

Isolation and hydrolysis of brain DNA was performed as previously described by Lodovici et al.\(^ {36}\). The hydrolyzed mixture was centrifuged, and the supernatant was injected into the HPLC. The separation of 8-OHDG was performed by a LC/Agilent 1200 series HPLC apparatus (USA), using UV detectors. For chromatographic separation, we used C18 reverse phase columns in series (Supelco, 5 pm, I.D. 0.46 x 25 cm); the eluting solution was H₂O /CH₂OH (85: 15 v/v) with 50 mM KH₂PO₄, pH 5.5 at a flow rate of 0.68 ml/minute. The UV detector was set at 245 nm\(^ {37}\). The resulting chromatogram identified the concentration from the sample as compared to that of the standard, purchased from Sigma Aldrich.

**Determination of adenosine tri-phosphate content (ATP, ADP and AMP) in brain tissues by HPLC**

Rapid high performance liquid chromatography method was developed for determination of adenine nucleotides in different tissues, which was used to investigate the relation between regional blood flow and tissue contents of compounds, involved in energy metabolism under physiological and pathological conditions. The detection of ATP was performed by HPLC.\(^ {38}\)

**Statistical analysis**

Statistical analysis of the obtained behavioral data was performed using nonparametric statistics Kruskal–Wallis test, followed by Mann–Whitney U test. Other parameters were done using Statistical Analysis Systems Institute (SAS, 1989). Significant differences
among means were evaluated using Duncan's Multiple Range Test. The following linear model was applied:
\[ Y_{ij} = \mu + \alpha_i + \xi_{ij} \]
where:
- \( Y_{ij} \) = Observation measured
- \( \mu \) = Overall mean
- \( \alpha_i \) = Experimental error assumed to be randomly distributed (\( \sigma^2 = 0 \)).

RESULTS
Behavioral test
Figure 2 shows the effect of an anti-hypertensive drug (Res), which induced rat depression model, confirmed by an open field behavioral test. The test shows a decrease in rearing and duration time in the peripheral zone. In contrast, other parameters of the open field for Res group showed a significant increase in grooming, duration at central zone, urination and defecation. According to Flux, HVE and their combination, obtained results demonstrated that the depression parameters are restored to the normal condition and markedly ameliorated from Res group.

Figure 3 shows the effect of Res in the spider shape of depression induction in rat model, resembling in increasing fluting, immobility time, decreased swimming, and climbing time. On the other hand, Flux group showed strength shape for climbing on another group and amelioration for swimming time with reduction in fluting time. In the same manner, HVE and Flux, plus HVE showed a marginal amelioration of the depression condition, which resulted in increased swimming time and decreased duration of fluting, or immobility time.

Liver functions
Obtained data of Table 1 shows initial reduction in liver function and leakage of enzymes from hepatocytes after sub-chronic dose of Res, which resulted in a real increase of ALT, AST and a significant decrease of TP, comparing with the control group. In the same manner, Flux showed a similar trend for hepatocytes degradation. In contrast, HVE did not show harmful effects and ameliorated liver function to almost a normal condition. It also decreased the side effect of Flux in the combination group, compared to control group.

Brain monoamines and their metabolites
The data in Table 2 suggests a significant attrition for monoamines, compared to the control group. In contrast, the groups, treated with Flux, HVE, and their combination showed results, almost similar to the control group and significantly different from the Res group.

Brain oxidative stress and neuronal cell energy
Table 3 shows a massive cell membrane degradation, presenting in more than triple level of MDA concentration compared to control group, markedly decreased endogenous antioxidant markers (GSH and SOD) and stimulated nitrositive radical and oxidation due to GSSG production. In the same manner, Flux still described with oxido-nitrositive stimulator and had no effect on antioxidant system. In contrast, the HVE mixed-treated group showed amelioration for cell membrane protective properties, which decreased MDA, GSSG, NO, and increased GSH and SOD, comparing with Res group.

DISCUSSION
Antihypertensive drugs, such as reserpine, are naturally extracted indole alkaloids, acting as a dopamine depletion agent, that inhibits several neurotransmitters. According to a planned investigated study, Res showed identical effects of reserpine as a depressive model demonstration in behavioral tests, which increased immobility and swimming or climbing time.
Table 1: Effect of Flux and/or HVE and their combination on serum liver function in reserpine-induced depressed rats model

| Groups                | Parameters | ALT IU/L  | AST IU/L  | TP g/dL    | Alb g/dL   | Glob g/dL | A/G       |
|-----------------------|------------|-----------|-----------|------------|------------|-----------|-----------|
| Control (n=6)         |            | 24.85 ± 0.80⁶ | 25.75 ± 0.97⁴ | 7.69 ± 0.22⁴ | 4.29 ± 0.13⁴ | 3.4 ± 0.14⁴ | 1.26 ± 0.04⁴b |
| Res (n=6)             |            | 49.84 ± 1.57³ | 55.5 ± 1.55⁴ | 6.94 ± 0.23³ | 3.99 ± 0.12³ | 2.95 ± 0.09³ | 1.35 ± 0.04³a |
| Res+Flux (n=6)        |            | 42.89 ± 1.60⁵ | 47.95 ± 1.72⁵ | 7.03 ± 0.21⁵ | 4.11 ± 0.13⁵ | 2.92 ± 0.11b | 1.4 ± 0.045a |
| HVE (n=6)             |            | 30.03 ± 1.09d | 36.58 ± 1.07d | 7.72 ± 0.25d | 4.16 ± 0.14d | 3.62 ± 0.11a | 1.16 ± 0.038b |
| Res+Flux+HVE (n=6)    |            | 36.95 ± 1.21c | 42.6 ± 1.60c | 7.55 ± 0.22c | 4.07 ± 0.12c | 3.48 ± 0.10a | 1.16 ± 0.046b |

Data are expressed as Mean ± S.E.M for six rats/group. ⁶, ³, ⁵, ⁴ means having different superscript letters in the same column differ significantly (p < 0.05).

Table 2: Effect of Flux and HVE and their combination on brain monoamines concentration in reserpine-induced depressed rats model

| Groups                | Parameters | NE µg/g tissue | DA µg/g tissue | 5HT µg/g tissue |
|-----------------------|------------|----------------|---------------|----------------|
| Control (n=6)         |            | 0.566 ± 0.021⁴ | 2.41 ± 0.094⁴ | 0.472 ± 0.017⁴ |
| Res (n=6)             |            | 0.277 ± 0.012d | 1.19 ± 0.033d | 0.24 ± 0.009d  |
| Res+Flux (n=6)        |            | 0.381 ± 0.012bc | 1.61 ± 0.029bc | 0.288 ± 0.012c |
| HVE (n=6)             |            | 0.353 ± 0.022d | 1.48 ± 0.066c | 0.314 ± 0.014b |
| Res+Flux+HVE (n=6)    |            | 0.435 ± 0.020b | 1.74 ± 0.078b | 0.359 ± 0.018b |

Data are expressed as Mean ± SEM for six rats/group. ⁶, ³, ⁴ means having different superscript letters in the same column differ significantly (p< 0.05)

Table 3: Effect of Flux and/or HVE on brain oxidative stress markers in reserpine-induced depressed rats model

| Groups                | Parameters | MDA nmol/g tissue | GSH µmol/g tissue | GSSG µmol/g tissue | NO µmol/g tissue | SOD U/g tissue |
|-----------------------|------------|-------------------|------------------|-------------------|-----------------|----------------|
| Control (n=6)         |            | 16.92 ± 0.41c     | 4.003 ± 0.26a    | 0.514 ± 0.02c     | 0.39 ± 0.02d    | 54.25 ± 1.88a  |
| Res (n=6)             |            | 55.10 ± 3.04a     | 1.583 ± 0.09c    | 1.41 ± 0.054a     | 1.03 ± 0.08a    | 22.98 ± 0.89a  |
| Res+Flux (n=6)        |            | 33.01 ± 1.90b     | 2.105 ± 0.21bc   | 0.954 ± 0.03ab    | 0.66 ± 0.05bc   | 34.62 ± 1.22d  |
| HVE (n=6)             |            | 24.95 ± 1.74d     | 2.963 ± 0.16b    | 0.745 ± 0.03b     | 0.58 ± 0.06c    | 48.62 ± 1.71b  |
| Res+Flux+HVE (n=6)    |            | 28.716 ± 1.65c    | 2.87 ± 0.17b     | 0.773 ± 0.03b     | 0.70 ± 0.05b    | 39.65 ± 1.45c  |

Data are expressed as Mean ± SEM for six rats/group. ⁶, ³, ⁴ means having different superscript letters in the same column differ significantly (p < 0.05)
Figure 2: Effect of Flux and/or HVE on behavioral open field test in reserpine-induced depressed rats model.

Table 4: Effect of Flux and/or HVE on brain cell energy in reserpine-induced depressed rats model

| Groups                  | Parameters                        | ATP µg/g tissue | ADP µg/g tissue | AMP µg/g tissue |
|-------------------------|-----------------------------------|-----------------|-----------------|-----------------|
| Control (n=6)           |                                   | 23.73 ± 1.08<sup>a</sup> | 12.68 ± 0.74<sup>a</sup> | 7.01 ± 0.35<sup>a</sup> |
| Res (n=6)               |                                   | 11.47 ± 0.26<sup>d</sup> | 5.01 ± 0.14<sup>d</sup>  | 3.09 ± 0.23<sup>c</sup>  |
| Res+Flux (n=6)          |                                   | 14.45 ± 0.51<sup>c</sup> | 7.10 ± 0.42<sup>c</sup>  | 4.10 ± 0.18<sup>c</sup>  |
| HVE (n=6)               |                                   | 18.64 ± 0.96<sup>b</sup> | 10.37 ± 0.41<sup>b</sup> | 5.95 ± 0.26<sup>b</sup>  |
| Res+Flux+HVE (n=6)      |                                   | 17.88 ± 0.61<sup>b</sup> | 9.14 ± 0.28<sup>b</sup>  | 5.16 ± 0.22<sup>b</sup>  |

Data are expressed as Mean ± S.E.M for 6 rats/group. <sup>a,b,c,d</sup> means having different superscript letters in the same column differ significantly (P<0.05)
Figure 3: Effect of Flux and/or HVE on behavioral force swimming test in reserpine induced depressed rats model.

Figure 4: Effect of Flux and/or HVE on brain monoamines concentration in reserpine induced depressed rat model. Data are expressed as Mean ± SEM for six rats/group. a, b, c means having different superscript letters in the same column differ significantly (p < 0.05).
That is due to monoamines depletion. In addition, depression model was confirmed by OFT by means of increased central duration time, defecation, urination and grooming behavior; in contrast, locomotor activity, resembling in peripheral zone and rearing time were decreased, comparing with the control group. The present finding showed that a reference drug SSRI stimulated serotonin production, stimulated locomotor activity through increasing clamping, fluting time and OFT excitatory parameters (rearing and duration of stay in peripheral zone). All the recorded results about HVE for behavioral test may bake to normal condition for each behavioral tests, but swimming time is more of a marker for normalized behavioral FST, than clamping, which reflects chemical serotonin stimulation and increased locomotor activity without abnormal excitation. These findings are in agreement with previous study of Preskorn et al. which proved, that the flavonoid (Resveratrol) stabilized behavioral state for Res induced depression, thus it was effective as a natural antidepressant, which may be capable of reversing the depressive-like effects of reserpine. Similarly, a combined treatment for behavioral tests showed the best treatment, which normalized swimming and decreased fluting time. Indeed, exerted beneficial effects for both herbal remedy and SSRI treatment with minor side effects. Present data showed a significant side effect for Res, which displayed toxic effects due to the indole alkaloids. The highest toxicity values of indole alkaloids were owing to tryptamine, which had the least active alkaloid and other chemicals to restrict the reason of phytotoxicity for auxins with an aromatic ring and a side chain which arise from changes of the length of the side chain and changes on the structure of the amino group. Res established a depression rat model via the decrease of all neurotransmitters and damaging liver and brain neurons. According to biochemical parameters, the Res group showed decreased level of endogenous antioxidants, increased redox status and decreased cell energy. All alterations were confirmed by histopathological examination, which reflects the evacuation and picnotic neurons and spreading neuropil in wide distribution. In the same manner, a previous study of Owens et al. showed that Res increases TBA, which resembles an increase in MDA concentration and decrease of GSH levels in brain and liver tissues. This could be due to the pathophysiology of multiple pathogenic factors, involved in depression and concurrent with monoaminergic depletion.

The SSRIs induced blocking the reuptake of serotonin, leading to increased concentration of the neurotransmitters in the synaptic cleft and, ultimately, to greater postsynaptic neuronal activity. Fluoxetine and its major metabolite, norfluoxetine, are highly active against serotonin transport and also may have antimigraine effects not found with the (R)-enantiomer of fluoxetine. The (R)-enantiomer of fluoxetine is active against serotonin transport and is short-acting. An increased synaptic availability of serotonin stimulates a large number of postsynaptic 5-HT receptor types. Stimulation of 5-HT3 receptors is hypothesized to contribute to common adverse effects, including gastrointestinal and sexual dysfunction. Demonstrated data clearly concurred
with Schatzberg\textsuperscript{44}, who found that the decrease in depression adult rats, treated with Flux might be due to neuroadaptive mechanisms via monoamines stabilization. On the other hand, presented data remarked beneficial effects for Flux-treated group, but in the same way showed the prissiness of side effects, resulting in liver alteration. Due to a lower ability to metabolize serotonin and a lower capacity of glomerular filtration rate, psychotropic drugs quickly produced craniofacial malformations for embryonic rats\textsuperscript{46}. Another side effect of SSRIs, that has been evaluated in experimental studies, is the decrease in brain cell energy, especially ATP content, which was confirmed by Süzme\textsuperscript{47}, who reported that fluoxetine and other SSRIs induced negative effects, which postulated bound SSRIs to sulphhydryl groups in the cell membrane and impaired ATP synthesis, by interacting with phospholipids. In the prissiness of data, liver alteration was confirmed by a histopathological examination. This fact is in agreement with Reichelt\textsuperscript{48}, who reported that the major finding of Flux treated rats was the development of hepatocellular hydropic vacuolar degeneration. Similarly, Sugimoto et al.\textsuperscript{49} examined hepatic glycogen content and confirmed that the vacuoles did not contain glycogen. Since hepatic protein contents decreased in parallel with the severity of hepatocellular vacuolar degeneration, the vacuoles were considered to be mainly associated with intracellular water accumulation. Insulin and glucagon were recently recognized as potent modulators of liver cell volume. These findings may be due to serotonin, a cause of hypoglycemia, and an increase in serum insulin levels\textsuperscript{50}. Insulin stimulates Na\textsuperscript{+}-H\textsuperscript{+} exchange, Na\textsuperscript{+}-K\textsuperscript{+}-2Cl transport, and Na\textsuperscript{+}-K\textsuperscript{+}-ATPase, and the concerted action of these transporters lead to cellular accumulation of K\textsuperscript{+}, Na\textsuperscript{+} and Cl\textsuperscript{−} and, consequently, cell swelling\textsuperscript{51}. The exposure of the brain to Res induced depression and subsequent oxidano-nitrositive stress, which is a one of the most important risk factors for neurodegenerative diseases. Hordeum vulgare extract can mitigate each afore negative effect due to its contents, which is rich in flavonoids, carotenoids, vitamins, and amino acids, especially tyrosine. According to the present study, HVE showed amelioration in liver function and decreased enzyme leakage to the blood stream. In addition, a decreased brain oxidano-nitrositive stress and normalized GSH and enzymatic antioxidant marker (SOD) were shown, which may be due to antioxidative properties. The obtained data are consistent with Hehl\textsuperscript{52}, who reported that HVE is a powerful antioxidant due to free radical scavenging activity, inhibition of lipoxygenase activity and inhibition of β-carotene co-oxidation in a linoleate model system. In the same manner, Boekema and Braun\textsuperscript{53} showed a significant decrease in MDA level whereas increase the SOD, GSH content and CAT activities with HVE, as compared to gentamicin-induced nephrotoxicity in adult male rats. According to the main active constituent of HVE for neuro-deficiency function (Tryptamine), it can be identified as a semi-essential aromatic amino acid\textsuperscript{54}. It is responsible for the syntheses of catecholamines (NE and DA), thyroid hormone and melanin pigmentation\textsuperscript{55}. The brain contains a large number of mitochondria and produces much energy through mitochondrial oxidative phosphorylation\textsuperscript{55}. The recovery of monoamines may normalize ATP and its metabolites ADP and AMP, or mild depletion, according to the depression model, may stimulate ATP as a neuromodulator for compensating DA depletion, or monoamines deficiency. In the present study, a combination of HVE extract with Flux effects on brain neurotransmitters showed effectiveness of D2 agonist and stimulate secretion via tyrosine rich extract that precursor of DA and tryptophane of serotonin stimulant\textsuperscript{56}. The focus of obtained data was to establish the mechanism, how barley ameliorates depression via tryptophane content. It has been identified that a large percentage of tryptophane increase in brain tryptamine concentration leads to accelerated synthesis of 5-HT\textsuperscript{57}. 

**CONCLUSION**

In conclusion, obtained data highlighted the vital and neural role of corrective depression, induced by reserpine with spontaneous treatment by HVE, stimulating monoamines, antioxidant status, decrease oxidano-nitrositive markers and increase cell energy capacity without side effects on liver. In contrast, SSRI drugs shown to induce liver damage.

**COMPETING INTERESTS**

None of the authors of this article have conflicting interests.

**AUTHORS’ CONTRIBUTIONS**

All authors contributed equally in the study design, interpretation of the data, and writing of the final manuscript.

**REFERENCES**

1. McKeever A, Agius M, Mohr P. Review of the epidemiology of major depressive disorder and its consequences for society and the individual. Psychiatra Danubina. 2017;29(3):222–31. PMID: 28993767.
2. Ferrari AJ, Somerville AJ, Baxter AJ, Norman R, Patten SB, Vos T, et al. Global variation in the prevalence and incidence of major depressive disorder: a systematic review of the epidemiological literature. Psychological Medicine. 2013;43(3):471–81. PMID: 22881756. Available from: 10.1017/S0033291712001511.

3. Hyman SE. The genetics of mental illness: implications for practice. Bulletin of the World Health Organization. 2000;78(4):455–63. PMID: 10885164.

4. Simon GE. Treating depression in patients with chronic disease: recognition and treatment are crucial; depression worsens the course of a chronic illness. The Western Journal of Medicine. 2001;175(5):292–3. PMID: 11694462. Available from: 10.1136/wmj.175.5.292.

5. Dunn EC, Brown RC, Dai Y, Rosand J, Nugent NR, Amstadter AB, et al. Genetic determinants of depression: recent findings and future directions. Harvard Review of Psychiatry. 2015;23(1):1–18. PMID: 25563565. Available from: 10.1097/HRP.0000000000000054.

6. Melle I, Larsen TK, Haahr U, Friis S, Johannesen JO, Opjordsmoen S, et al. Prevention of negative symptom psychopathologies in first-episode schizophrenia: two-year effects of reducing the duration of untreated psychosis. Archives of General Psychiatry. 2008;65(6):334–40. PMID: 18519821. Available from: 10.1001/archpsyc.65.6.634.

7. Rooden HG, de Waart V, van der Kroft P. Community reinforcement and family training: an effective option to engage treatment-resistant substance-abusing individuals in treatment. Addiction (Abingdon, England). 2010;105(10):1729–38. PMID: 20626372. Available from: 10.1111/j.1360-0443.2010.03016.x.

8. Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H, et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science. 2003;301(5631):386–9. PMID: 12869766. Available from: 10.1126/science.1083968.

9. Patten SB. Are the Brown and Harris "vulnerability factors" risk factors for depression? Journal of Psychiatry & Neuroscience. 1991;16(5):267–71. PMID: 1797101.

10. van der Deure WM, Appelhof BC, Peeters RP, Wiersma WG, Wekking EM, Huyser J, et al. Polymorphisms in the brain-specific thyroid hormone transporter DATP1C1 are associated with fatigue and depression in hypothyroid patients. Clinical Endocrinology. 2008;69(5):804–11. PMID: 18410547. Available from: 10.1111/j.1365-2265.2008.03267.x.

11. Ferguson JM, Ferguson MD. SSRI antidepressant medications: adverse effects and tolerability. Primary Care Companion to the Journal of Clinical Psychiatry. 2001;3(1):22–7. PMID: 15048872. Available from: 10.1016/S1365-2265(01)00054-X.

12. Marken PA, Munro JS. Selecting a selective serotonin reuptake inhibitor: clinically important distinguishing features. Primary Care Companion to the Journal of Clinical Psychiatry. 2000;2(6):205–10. PMID: 15014630. Available from: 10.4088/PCC.v02n0602.

13. Frasure-Smith N, Lespérance F, Juneau M, Talajic M, Bourassa MG. Gender, depression, and one-year prognosis after myocardial infarction. Psychosomatic Medicine. 1996;58(1):126–37. PMID: 10024065. Available from: 10.1097/00006842-199901000-00006.

14. Goldstein BJ, Goodnick PJ. Selective serotonin reuptake inhibitors in the treatment of affective disorders, 3: tolerability, safety, and pharmacoeconomics. J Psychopharmacol. 1998;8(8):555–87.

15. Nelson JC. Safety and tolerability of the new antidepressants. The Journal of Clinical Psychiatry. 1997;58(6):26–31. PMID: 9227670.

16. Frich W, Aman P, Tetens I. Whole grain foods and health - a Scandinavian perspective. Food & Nutrition Research. 2013;57(6):57–66. PMID: 23411562. Available from: 10.3402/fnr.v57i6.18503.

17. Baik BK, Ulrich SE. Barley for food: characteristics, improvement, and renewed interest. J Cereal Sci. 2008;48(23):342–4.
assay for superoxide dismutase. European Journal of Biochemistry. 1974;47(3):469–74. PMID:2415654. Available from: 10.1111/j.1432-1033.1974.tb03714.x.

36. Lodovici M, Casalini C, Brianzi C, Dolara P. Oxidative liver DNA damage in rats treated with pesticide mixtures. Toxicology. 1997;117(1):55–60. PMID:9020199. Available from: 10.1016/ 50300-883X(97)03553-6.

37. Tee link T, Hennekes M, Bussenaker J, Groeneveld J. Immunohistodetection of dopamine and histamine in amygdala and hypothalamus of rats. Neuroendocrinology. 1993;58(1):278–83. PMID:8260235. Available from: 10.1006/anab.1993.1488.

38. Banchroft JD, Stevens A, Turner DR. Theory and practice of histological techniques. New York, London, San Francisco, Tokyo: Churchill Livingstone; 1996.

39. Yaffe D, Forrest LR, Schuldiner S. The ins and outs of vesicular monoamine transporters. The Journal of General Physiology, 2018;150(5):671–82. PMID:29666153. Available from: 10.1085/jgp.201711980.

40. Preskorn SH, Ross R, Stanga CY. Selective serotonin reuptake inhibitors. In: Preskorn SH, Feighner JP, Stanga CY, Ross R, editors. Antidepressants: Past, Present and Future. vol. 157 of Handbook of Experimental Pharmacology. Berlin, Germany: Springer; 1996. p. 241-62. Available from: 10.1007/978-3-642-18500-7.

41. Owens JM, Knight DL, Nemeroff CB. Second generation SSRIS: Human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry. 2002;52(5):350–5. Available from: 10.1016/S0006-3223(01)01145-3.

42. Fuller RW, Snoddy HD, Krushinski JH, Robertson DW. Comparison of norfluoxetine enantiomers as serotonin uptake inhibitors. Neuropharmacology. 1992;31(10):997–1000. PMID:1279447. Available from: 10.1016/0028-3908(92)90100-D.

43. Azmitia EC, Strasburger J, Rios JC, Whitaker-Azmitia PM. 5-HT1A agonist and dexamethasone reversal of para-chloroamphetamine induced loss of MAP-2 and synaptophysin immunoreactivity in adult rat brain. Brain Research. 1995;677(2):181–92. PMID:7552242. Available from: 10.1016/0006-8993(95)00051-Q.

44. Schatzberg A, Cole J. Manual of clinical psychopharmacology. Washington (DC): American Psychiatric Press; 1991.

45. Shuey DL, Sadler TW, Lauder JM. Serotonin as a regulator of craniofacial morphogenesis: site specific malformations following exposure to serotonin uptake inhibitors. Teratology. 1992;46(4):367–78. PMID:1412065. Available from: 10.1002/tera.1420460407.

46. Reid TE, Kumar K, Wang XS. Predictive in situ studies of human S-hydroxytryptamine reuptake substrate 2B (S-HT2B) and valvular heart disease. Current Topics in Medicinal Chemistry. 2013;13(11):1353–62. PMID:23675941. Available from: 10.2174/15680266113139990039.

47. Süzme R, Gürdol F, Deniz G, Ozden T. Response in DNA ploidy of hepatocytes to tamoxifen and/or melatonin in vivo. Research Communications in Molecular Pathology and Pharmacology. 2001;109(5–6):275–86. PMID:12889511.

48. Reichelt ME, Mellor KM, Curl CL, Stapleton D, Delbridge LM. Myocardial glycation - a specific glycan handling response to metabolic stress is accentuated in the female heart. Journal of Molecular and Cellular Cardiology. 2013;65:67–75. PMID:24080183. Available from: 10.1016/j.yjmcc.2013.09.014.

49. Sugimoto Y, Kimura I, Yamada J, Watanabe Y, Takeuchi N, Horisaka K. Effects of serotonin on blood glucose and insulin levels of glucose- and streptozotocin-treated mice. Japanese Journal of Pharmacology. 1990;54(1):93–6. PMID:2148781. Available from: 10.1254/jp.54.93.

50. Hallbrucker C, von Dahl S, Lang F, Gerok W, Haussinger D. Inhibition of hepatic proteolysis by insulin. Role of hormone-induced alterations of the cellular K+ balance. European Journal of Biochemistry. 1991;199(2):467–74. PMID:2070798. Available from: 10.1111/j.1432-1033.1991.tb16145.x.

51. Goupy P, Hugues M, Bovin P, Amiot MJ. Antioxidant composition and activity of barley (Hordeum vulgare) malt extracts and of isolated phenolic compounds. Journal of the Science of Food and Agriculture. 1999;79(12):1625–34. Available from: 10.1002/jsfa.1097-0010(199909)79:12<1625::AID-JSFA411>3.0.CO;2-8.

52. Held PK. Disorders of tyrosine catabolism. Molecular Genetics and Metabolism. 2006;88(2):103–6. PMID:16773741. Available from: 10.1016/j.mgen.2006.04.002.

53. Boekema EJ, Braun HP. Supramolecular structure of the mitochondrial oxidative phosphorylation system. The Journal of Biological Chemistry. 2007;282(1):1–4. PMID:17102127. Available from: 10.1074/jbc.R600031200.

54. Khan A, Schwartz KA, Kolts RL, Brown WA, BMI, sex, and antidepressant response. Journal of Affective Disorders. 2007;99(1- 3):101–6. PMID:17010444. Available from: 10.1016/j.jad.2006. 08.027.

55. Muller R, Liu YY, Brent GA. Thyroid hormone regulation of metabolism. Physiological Reviews. 2014;94(2):355–82. PMID:24692351. Available from: 10.1152/physrev.00026.2013.

56. Robinson JO, Standing HR, DeVito EE, Cools R, Sahakian BJ. Dopamine precursor depletion improves punishment prediction during reversal learning in healthy females but not males. Psychopharmacology. 2010;211(2):187–95. PMID:20495788. Available from: 10.1007/s00213-010-1880-1.

57. Warsh JJ, Godse DD, Stancer HC, Chan PW, Cosicina DV. Brain tryptamine in rats by a new gas chromatography-mass fragmentographic method. Biochemical Medicine. 1977;18(1):10–20. PMID:901424. Available from: 10.1016/ 0006-2944(77)90045-X.